3 days popular7 days popular1 month popular3 months popular

Promoting Clinical Trials For MENA Region, 3-4 October 2012 Dubai, UAE

Recent studies have shown that in an attempt to save time and resources, International Pharmaceutical Companies are increasingly out-sourcing clinical trials to developing countries such as and the MENA region. This was highlighted in a new report by industry experts GBI Research.

The increment of productivity in clinical trials is changing the business model of the . International pharmaceutical companies are demanding faster, more effective and lower-cost clinical trial processes. For this reason, pharmaceutical giants are expanding clinical trial programs into emerging regions.

The combination of a high population against a low number of current clinical trials as well as a growing market for pharmaceuticals, has transformed the MENA region into an appealing area for expanding clinical-research opportunities.

According to recent reports, the total number of clinical trials has risen considerably in the Middle East and Eastern Europe compared to the US where it has fallen by 20% in the last 10 years.

“As the CRO market in the MENA region is relatively young, we believe we are perfectly positioned to grow the industry, learning from other emerging markets that started before us,” CEO from a local MENA’s CRO.

These developments will be highlighted by Qatalyst Global at the upcoming Promoting Clinical Trials for MENA region, taking place in , during the 3rd – 4th October 2012 where the conference is aiming to raise the profile of MENA and Turkey as a key region to conduct clinical research, while also recognising the challenges the region can also present.

This strategic meeting will bring together a delegation that includes both international and local Pharmaceutical Companies, Regulatory Bodies, Government Officials and CRO’s to improve and promote drug and research development in the MENA region.

Confirmed speakers include: Rania Bader, Director of Medical Application, EHS; Martin Dossenbach, Senior Medical Director, Turkey, ME, Africa & CIS, Eli Lilly; Hilal Hilbars, Head of Clinical Trials Department, Turkish Medicines & ; Melanie Rolli, Head of Medical Affairs, Novartis; , Senior Ofiicer – Medical Research, Health Authority Abu Dhabi. They will provide a multidisciplinary approach to tackle the fundamental challenges in Clinical Trials in developing regions by identifying the emerging Threats and Trends.


Book on or before 26th September and save up to 50% off standard rates. To benefit from our incentive pricing at $999 instead of $1650 please contact Qatalyst Global and quote “MNT”. Team booking of 2 people will include a third complimentary delegate pass.

Register now at +44 (0) 2083201329 or email [email protected]


Qatalyst Global